Seeking to further diversify its product lines, specialty pharma Amag Pharmaceuticals Inc. will pay $600 million in cash plus $75 million in stock, or approximately 3.2 million newly issued shares, to purchase privately held Lumara Health Inc. (previously K-V Pharmaceutical Co.). Lumara shareholders will receive another $350 million, contingent on the achievement of sales milestones.